WASHINGTON—Digestive Disease Week 2024 was overflowing with research on all GI topics. Miguel Regueiro, MD, the chief of the Digestive Disease Institute and a professor of medicine at Cleveland Clinic in Cleveland, sat down with Gastroenterology & Endoscopy News to highlight some of the most noteworthy research in inflammatory bowel disease.
Dr. Regueiro mentioned several abstracts and sessions, including:
- Rubin et al. The efficacy and safety of guselkumab as maintenance therapy in patients with moderately to severely active ulcerative colitis: Results from the phase 3 quasar maintenance study (abstract 759)
- Dubinsky et al. Risankizumab versus ustekinumab for the achievement of clinical remission and reduction in inflammatory biomarkers in patients with moderate-to-severe Crohn’s disease: Results from the phase 3b sequence trial (abstract 763)
- Raffals et al. Efficacy and safety of darvadstrocel treatment in patients with complex perianal fistulas and Crohn’s disease: Results from the global ADMIRE-CD II phase 3 study (abstract 761)
- Loftus et al. Achievement of corticosteroid-free clinical, endoscopic, and histologic outcomes in patients with moderately to severely active ulcerative colitis treated with risankizumab: Results from the command study (abstract Su1751)
- Sehgal et al. Safety and clinical effectiveness of GLP-1 agonists in inflammatory bowel disease patients (abstract 721)
- Ha & Limketkai (moderators). IBD Adverse Events Related to Therapy: Focus on Small Molecules (session 4280)
Interested in more? Check out additional DDW 2024 coverage from Gastro Endo News, and read issues of Dr. Regueiro’s column The Regueiro Report.
—GEN Staff
